HLA A24 Associated Tumor Immunity in HER2/neu Positive Breast Cancer

Ravi Pratap singh, Chinta mani, AK Mandal

Abstract


Breast carcinoma is the most common tumor in women and it has resulted in significant morbidity and mortality. Recognition of tumor-associated antigens (TAA) by HLA class I-restricted CD8+ T cells is fundamental for the detection and destruction of malignant cells. HLA A24 has been shown to be associated with presenting peptides in breast carcinoma, which can be targeted for cancer immunotherapy. Overexpression of the HER2 receptor tyrosine kinase is associated with more advanced-stage disease at presentation and a rapidly progressive clinical course. Here we present a case of a 57-year-old female, who presented with a left breast lump. On histopathological examination, diagnosis of infiltrating ductal carcinoma was made . The patient had ER, PR negative and HER/neu positive cancer with nodal metastasis to supraclavicular lymph nodes. Course of Antracycline-based chemotherapy was started. Patient showed no signs of recurrence till the time of writing the article.


Keywords


HLA A24, Breast cancer, HER2/neu, Infiltrating ductal carcinoma

Full Text:

PDF

References


Three-year report of population based cancer

registries: 2012-2014. [online] Available at:

http://ncrpindia.org/ALL_NCRP_REPORTS/PBCR_

REPORT_2012_2014/ALL_CONTENT/PDF_Printed

_Version/References_Printed.pdf [Accessed 30

Apr. 2017].

Leong PP, Muhammad R, Ibrahim N et al. HLA-A

and breast cancer in West Peninsular Malaysia.

Med Oncol 2011 Mar; 28(1): 51-56.

Azuma K, Shichijo S, Shomura H et al.

Identification of HER2/neu derived peptides

capable of inducing both cellular and humoral

immune responses in HLA-A24 positive breast

cancer patients. Breast Cancer Res Treat 2004 Jul;

(1): 19-29.

Kaneko K, Ishigami S, Kijima Y et al. Clinical

implication of HLA class I expression in breast

cancer. BMC Cancer 2011; 11: 454

Tiriveedhi V, Sarma NJ, Subramanian V et al.

Identification of HLA-A24 restricted CD8+

cytotoxic t-cell epitopes derived from

mammaglobin-A, a human breast cancer

associated antigen. Hum Immunol 2012 Jan;

(1): 11-16.

Nocera NF, Lee MC, De La Cruz LM et al. Restoring

lost anti-HER-2 Th1 immunity in breast cancer: A

crucial role for Th1 cytokines in therapy and

prevention. Frontiers in pharmacology 2016;

(356): 1-12.

Inoue M, Mimura K, Izawa S et al. Expression of

MHC class I on breast cancer cells correlates

inversely with HER2 expression. OncoImmunology

;c1(7): 1104-10.

Watson MA, Dintzis S, Darrow CM et al.

Mammaglobin expression in primary, metastatic,

Singh RP et al. Rec. Adv. Path. Lab. Med. 2017; 3(2)

ISSN: 2454-8642 16

and occult breast cancer. Cancer Res 1999;

(13): 3028.

Finn OJ, Jerome KR, Henderson RA et al. MUC-1

epithelial tumor mucin-based immunity and

cancer vaccines. Immunol Rev 1995; 145: 61.

Peoples GE, Goedegebuure PS, Smith R et al.

Breast and ovarian cancer-specific cytotoxic T

lymphocytes recognize the same HER2/neuderived

peptide. Proc Natl Acad Sci USA 1995;

(2): 432.

Tan M, Yu D. Molecular mechanisms of erbB2-

mediated breast cancer chemoresistance.

Advances in Experimental Medicine and Biology

; 608: 119-29


Refbacks

  • There are currently no refbacks.


Copyright (c) 2017 Recent Advances in Pathology & Laboratory Medicine